Anti-Puma Biotechnology Inc Institutional Investors Sentiment Runs Low in Q1 2018

June 7, 2018 - By Migdalia James

Sentiment for Puma Biotechnology Inc (NYSE:PBYI)

Puma Biotechnology Inc (NYSE:PBYI) institutional sentiment decreased to 1.14 in 2018 Q1. Its down -0.51, from 1.65 in 2017Q4. The ratio dived, as 90 investment professionals increased and started new equity positions, while 79 sold and decreased holdings in Puma Biotechnology Inc. The investment professionals in our partner’s database now own: 34.13 million shares, down from 34.70 million shares in 2017Q4. Also, the number of investment professionals holding Puma Biotechnology Inc in their top 10 equity positions decreased from 5 to 4 for a decrease of 1. Sold All: 35 Reduced: 44 Increased: 69 New Position: 21.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. The company has market cap of $1.83 billion. The Company’s drug candidates include PB272 ) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). It currently has negative earnings. The firm also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

The stock decreased 4.35% or $2.2 during the last trading session, reaching $48.35. About 243,843 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has declined 33.50% since June 7, 2017 and is downtrending. It has underperformed by 46.07% the S&P500.

Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on August, 8. They expect $-1.07 earnings per share, up 49.05 % or $1.03 from last year’s $-2.1 per share. After $-0.65 actual earnings per share reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts 64.62 % negative EPS growth.

Redmile Group Llc holds 2.88% of its portfolio in Puma Biotechnology, Inc. for 1.10 million shares. Partner Fund Management L.P. owns 2.03 million shares or 2.81% of their US portfolio. Moreover, Venbio Select Advisor Llc has 2.68% invested in the company for 825,368 shares. The New York-based Orbimed Advisors Llc has invested 2.23% in the stock. Partner Investment Management L.P., a California-based fund reported 27,154 shares.

Since January 1, 0001, it had 0 buys, and 5 insider sales for $1.46 million activity.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Ratings Coverage

Ratings analysis reveals 63% of Puma Biotechnology’s analysts are positive. Out of 8 Wall Street analysts rating Puma Biotechnology, 5 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $70.0 while the high is $147.0. The stock’s average target of $97.75 is 102.17% above today’s ($48.35) share price. PBYI was included in 14 notes of analysts from January 22, 2018. The rating was maintained by JP Morgan on Wednesday, January 24 with “Overweight”. The company was maintained on Friday, May 11 by Stifel Nicolaus. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, January 24. Bank of America maintained it with “Buy” rating and $115 target in Wednesday, January 24 report. The firm has “Buy” rating given on Monday, January 22 by Credit Suisse. The firm has “Equal-Weight” rating by Barclays Capital given on Thursday, April 12. The stock has “Buy” rating by Stifel Nicolaus on Friday, March 9. On Thursday, May 10 the stock rating was maintained by Citigroup with “Buy”. The rating was maintained by Citigroup on Wednesday, January 24 with “Buy”. As per Friday, March 2, the company rating was maintained by Barclays Capital.

Another recent and important Puma Biotechnology, Inc. (NASDAQ:PBYI) news was published by Streetinsider.com which published an article titled: “Puma Biotech (PBYI) Highlights Interim Data of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab …” on June 04, 2018.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: